Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial

Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: a machine learning analysis of the DESIRES trial

(2022) Satoshi Ebata et al.   RHEUMATOLOGY

Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis

(2021) Sasimon Borrirukwisitsak et al.   CLINICAL RHEUMATOLOGY

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial

(2021) Roham T Zamanian et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease

(2021) Joanna Tieu et al.   Frontiers in Immunology

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

(2021) Satoshi Ebata et al.   Lancet Rheumatology

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial

(2021) Dinesh Khanna et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model

(2021) Takemichi Fukasawa et al.   eLife

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

(2021) L Boekel et al.   Lancet Rheumatology

Systemic sclerosis-associated interstitial lung disease

(2020) Apostolos Perelas et al.   Lancet Respiratory Medicine

Emerging targets of disease-modifying therapy for systemic sclerosis

(2019) Elizabeth R. Volkmann et al.   Nature Reviews Rheumatology

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

(2019) Muriel Elhai et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti‐topoisomerase I‐positive systemic sclerosis‐associated interstitial lung disease

(2019) Satoshi Ebata et al.   JOURNAL OF DERMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Systemic sclerosis

(2017) Christopher P Denton et al.   LANCET

Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis

(2015) Silvia L. Bosello et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Systemic sclerosis

(2015) Yannick Allanore et al.   Nature Reviews Disease Primers

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

(2014) Suzana Jordan et al.   ANNALS OF THE RHEUMATIC DISEASES

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

(2013) Frank van den Hoogen et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis

(2009) Robert Lafyatis et al.   ARTHRITIS AND RHEUMATISM

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

(2009) Dimitrios Daoussis et al.   RHEUMATOLOGY

Interstitial Lung Disease in Systemic Sclerosis

(2008) Nicole S. L. Goh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

(2008) V Smith et al.   ANNALS OF THE RHEUMATIC DISEASES